On the need for metaphysics in psychedelic therapy and research
This hypothesis paper (2023) proposes integrating metaphysical experiences from psychedelic-assisted therapy with metaphysics, offering a Metaphysics Matrix and Metaphysics Matrix Questionnaire to aid in this process. By fusing philosophy with practical science, the text argues that patients may receive additional benefits during the integrative phase of therapy.
Authors
- Sjöstedt-Hughes, P.
Published
Abstract
The essential proposal of this text is that psychedelic-induced metaphysical experiences should be integrated and evaluated with recourse to metaphysics. It will be argued that there is a potential extra benefit to patients in psychedelic-assisted therapy if they are provided with an optional, additional, and intelligible schema and discussion of metaphysical options at the integrative phase of the therapy. This schema (the “Metaphysics Matrix”) and a new Metaphysics Matrix Questionnaire (“MMQ”) stemming therefrom will be presented, the latter of which can also be used as an alternative or additional tool for quantitative measurement of psychedelic experience in trials. Metaphysics is not mysticism, despite some overlap; and certainly not all psychedelic experience is metaphysical or mystical-all three terms will be defined and contrasted. Thereafter psychedelic therapy will be presented and analysed in order to reveal the missing place for metaphysics. Metaphysics, with epistemology (theory of knowledge) and axiology (ethics and aesthetics), is a defining branch of Philosophy. Metaphysics, in contrast to mysticism, is considered to be based on argument rather than pure revelation. Thus, in psychedelic-assisted psychotherapy one sees here the potential bridge between reason-based philosophy and practical therapy-or, more broadly, with psychedelic-assisted psychotherapy there is the potential and mutually beneficial fusion of philosophy with practical science.
Research Summary of 'On the need for metaphysics in psychedelic therapy and research'
Introduction
Noorani proposes that metaphysics should be explicitly incorporated into the integrative phase of psychedelic-assisted psychotherapy and into psychedelic research. The paper argues that many therapeutically salient psychedelic experiences are metaphysical in character and that providing patients with an optional, intelligible schema for understanding metaphysical options could strengthen integration and potentially extend clinical benefits. To support this, the author introduces a practical toolset: a Metaphysics Matrix that maps broad ontological positions and a Metaphysics Matrix Questionnaire (MMQ) intended both as an integration aid and as a quantitative instrument for trials. The introduction situates the proposal in historical and conceptual context, distinguishing metaphysics from mysticism and from empirical science. Noorani frames metaphysics as a long-standing branch of philosophy concerned with the fundamental nature of reality and suggests that many psychedelic experiences are intelligible as experiences of established metaphysical systems. The core conjecture is that Metaphysics Integration—an optional, additional strand within the standard preparatory, dosing, and integration phases of psychedelic-assisted psychotherapy—will help participants make lasting sense of metaphysical experiences and thereby improve long-term outcomes. The MMQ is presented as a complementary tool for research measurement and for providing concise definitions of the metaphysical positions used throughout the paper.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Topic
- APA Citation
Sjöstedt-Hughes, P. (2023). On the need for metaphysics in psychedelic therapy and research. Frontiers in Psychology, 14. https://doi.org/10.3389/fpsyg.2023.1128589
References (19)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Krupitsky, E. M., Grinenko, A. Y. · Journal of Psychoactive Drugs (1997)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J. et al. · Frontiers in Psychiatry (2021)
Morgan, C. J. A., McAndrew, A., Stevens, T. et al. · Current Opinion in Behavioral Sciences (2017)
Show all 19 referencesShow fewer
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Rothberg, R. L., Azhari, N., Haug, N. A. et al. · Journal of Psychopharmacology (2020)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Sanders, J. W. · ACS Pharmacology and Translational Science (2021)
Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Cited By (2)
Papers in Blossom that reference this study
Robinson, O., Evans, J., Luke, D. et al. · Frontiers in Psychology (2024)
Argyri, E. K., Evans, J., Luke, D. et al. · SSRN (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.